Patrick Burnett Sells 684 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Patrick Burnett sold 684 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $23.61, for a total transaction of $16,149.24. Following the transaction, the insider owned 120,466 shares in the company, valued at approximately $2,844,202.26. The trade was a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Patrick Burnett also recently made the following trade(s):

• On Monday, March 2nd, Patrick Burnett sold 6,287 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $25.18, for a total transaction of $158,306.66.

Arcutis Biotherapeutics Trading Down 14.5%

NASDAQ ARQT opened at $20.66 on Friday. Arcutis Biotherapeutics, Inc. has a twelve month low of $12.72 and a twelve month high of $31.77. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.99 and a current ratio of 3.17. The stock has a market cap of $2.58 billion, a price-to-earnings ratio of -688.44 and a beta of 1.58. The firm’s 50 day moving average price is $23.65 and its two-hundred day moving average price is $25.77.

Arcutis Biotherapeutics (NASDAQ:ARQT) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.07). Arcutis Biotherapeutics had a negative return on equity of 1.47% and a negative net margin of 0.57%.The firm had revenue of $105.40 million for the quarter, compared to analysts’ expectations of $103.68 million. Equities analysts anticipate that Arcutis Biotherapeutics, Inc. will post 0.18 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ARQT. Wall Street Zen cut shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Mizuho lowered their price target on shares of Arcutis Biotherapeutics from $37.00 to $35.00 and set an “outperform” rating on the stock in a report on Monday, March 2nd. HC Wainwright boosted their price target on shares of Arcutis Biotherapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Needham & Company LLC restated a “buy” rating and set a $36.00 price target on shares of Arcutis Biotherapeutics in a report on Thursday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a report on Friday, March 27th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $34.00.

Institutional Investors Weigh In On Arcutis Biotherapeutics

A number of large investors have recently bought and sold shares of ARQT. Johnson Investment Counsel Inc. bought a new stake in Arcutis Biotherapeutics in the third quarter worth $30,000. SBI Securities Co. Ltd. boosted its holdings in Arcutis Biotherapeutics by 325.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,089 shares of the company’s stock worth $32,000 after purchasing an additional 833 shares in the last quarter. Global Retirement Partners LLC bought a new stake in Arcutis Biotherapeutics in the fourth quarter worth $35,000. EverSource Wealth Advisors LLC boosted its holdings in Arcutis Biotherapeutics by 124.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock worth $37,000 after purchasing an additional 698 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its holdings in Arcutis Biotherapeutics by 209.0% in the fourth quarter. NewEdge Advisors LLC now owns 1,545 shares of the company’s stock worth $45,000 after purchasing an additional 1,045 shares in the last quarter.

More Arcutis Biotherapeutics News

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Commercial and clinical momentum: Q1 net product revenue for ZORYVE was $105.4M (up ~65% YoY), the company reported positive operating cash flow, submitted an sNDA to expand ZORYVE to infants 3–24 months, completed pediatric MUSE enrollment, initiated a Phase 1a/1b for ARQ?234, and expanded the salesforce/primary care buildout — all support continued top?line growth and pipeline optionality. Arcutis Announces First-Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analyst support: Needham reaffirmed a Buy rating with a $36 price target (mid?$30s Street consensus / “Moderate Buy”), which underpins upside expectations versus current levels and can stabilize sentiment over the medium term. Needham Reaffirms Buy, $36 PT
• Neutral Sentiment: Mixed Q1 financials: Revenue slightly beat estimates ($105.4M vs. ~$103.7M) but GAAP EPS missed materially (loss of $0.09 vs. expected loss of ~$0.02), highlighting ongoing margin/expense pressure as the company invests in growth. Q1 Loss, Revenue Beat (Zacks)
• Neutral Sentiment: Earnings call detail available: management commentary and slide deck / transcript provide additional context on commercialization cadence, seasonality, and SG&A investment — important for assessing whether EPS pressure is transitory. Earnings Presentation Earnings Call Transcript
• Negative Sentiment: Clustered insider selling: multiple insiders — including directors and executives (Howard Welgus, Masaru Matsuda, Todd Watanabe, CFO Latha Vairavan and others) — sold shares in early May under pre?arranged Rule 10b5?1 plans to cover tax on vested awards. Filings state routine/tax reasons, but the concentrated activity can create short?term selling pressure. Insider Selling Details

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.